RNA-triggered CRISPR cell kill & North Korea–Russia bridge near completion - News (May 8, 2026)

In science and health, a new twist on CRISPR is getting a lot of attention. Researchers say the enzyme Cas12a2 can be programmed to wipe out eukaryotic cells only when a chosen RNA transcript is present. In plain terms: instead of just editing DNA, this system can act like a highly selective “on-switch” for cell death—triggering only in cells that are expressing the target message. The early demonstrations include selectively knocking down HPV-positive cancer cells and distinguishing a well-known KRAS mutation in lab tests. It’s still early, and delivery and safety remain big hurdles, but the significance is clear: this could become a new way to remove the “right” cells while sparing the rest.

Another major biomedical headline: an experimental drug called daraxonrasib is raising expectations in advanced pancreatic cancer—one of the hardest cancers to treat because it’s often found late and resists many therapies. Early results suggest that adding the drug to standard chemotherapy may significantly extend survival compared with chemotherapy alone. Researchers also reported encouraging survival in patients who had already been through prior treatments. Regulators have moved quickly, including fast-tracking and expanded access, but doctors are also watching side effects closely—particularly painful skin reactions and digestive problems. If later results hold up, this could reshape the standard playbook for a disease that badly needs better options.

Staying with infectious disease: scientists have isolated unusually potent measles-neutralizing antibodies from a vaccinated adult, and early animal tests suggest these antibodies might reduce viral levels when given shortly after infection. That’s notable because measles outbreaks in the U.S. have renewed worries about protecting people who can’t easily benefit from vaccination—especially infants too young for routine shots and those with weakened immune systems. Researchers stress this wouldn’t replace vaccination, which remains the most effective shield at the population level. But as a targeted, after-exposure option, it could add a valuable layer of protection if the approach translates to humans.

And one more from the frontier of biology: scientists are mapping what’s sometimes called the human “dark proteome”—tiny microproteins produced from genome regions long assumed to be noncoding. Using methods that reveal what cells are actually translating, teams are finding microproteins linked to core processes like cell division and DNA repair, and some that appear specific to cancer cells. The reason this matters is simple: if these microproteins are real and functional—and the evidence increasingly says they are—then human biology includes a bigger set of moving parts than traditional gene catalogs suggested. That could open up new diagnostic markers and fresh drug targets, including targets that sit on the surface of tumor cells.

Turning to geopolitics, satellite imagery reviewed by BBC Verify indicates the first road bridge between North Korea and Russia is close to completion. The crossing spans the Tumen River near an existing rail link, and new roads and border facilities suggest it’s meant for regular, high-volume use. On its face, that’s trade infrastructure. But analysts say it could also make it easier to move military-related goods as ties deepen between Pyongyang and Moscow—ties that have drawn intense scrutiny since North Korea has been accused of supplying Russia with weapons, labor, and even troops connected to the war in Ukraine. Russia says the bridge should be finished by mid-June, a quick timeline that underscores how fast this relationship is hardening into something longer-term.

Meanwhile, Western intelligence officials are warning that Russia has escalated attempted targeted killings across Europe since the invasion of Ukraine—broadening beyond defectors to include activists and other perceived enemies, as well as supporters of Ukraine. Investigators in several countries describe surveillance and disrupted plots, and they say criminal proxies are increasingly used to lower the risk for Russian operatives and muddy attribution. Even when plots fail, officials argue the impact is real: it intimidates dissidents, strains security services, and sends a message that distance from Russia doesn’t guarantee safety. Moscow has denied responsibility for such operations.

In the Middle East and global trade, France is moving its Charles de Gaulle carrier strike group south of the Suez Canal into the Red Sea, as President Emmanuel Macron describes preparations for a possible French-British defensive mission linked to restoring maritime security around the Strait of Hormuz. With the Iran war disrupting shipping and leaving vessels stranded, energy markets and insurers are reacting sharply—driving up the cost, and in some cases the willingness, to transit the route. France says this would be separate from a U.S.-led effort and framed under international law, but also notes it would depend on conditions improving and on regional consent. The bigger story here is Europe trying to protect critical trade arteries while also carving out a more independent security role.

And in tech policy, Ireland has welcomed a provisional EU agreement to ban AI tools designed to generate child sexual abuse material or non-consensual intimate images of identifiable people. The deal would bar such systems from being sold in the EU, and it also pushes developers of more general tools to build in reasonable safeguards to prevent that kind of misuse. The move follows high-profile controversy and investigations around alleged deepfake abuse, and it closes a gap EU officials acknowledged in earlier rules. For everyday users, the takeaway is that Europe is setting a clearer line: if a system is built for exploitation—or predictably enables it without safeguards—it won’t be treated as “just another app.”